RecruitingNot Applicable

68Ga-PSMA PET/CT for Ra223 Assessment

Taiwan52 participantsStarted 2022-03-02

Plain-language summary

Primary objective: i.The primary objective is to compare the diagnostic positivity in progression of 68Ga-PSMA PET and Bone scan. Secondary objectives: i.The correlation between PET osseous tumor burden index and Alk-P level ii.The correlation between PET osseous tumor burden index and PSA level

Who can participate

Age range40 Years – 85 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Males with 40-85 years of age and life expectancy more than 3 months
✓. Patient was diagnosed as mCRPC, and meet the standard criteria of using 223Ra-dichloride (symptomatic bone metastasis, at least two bone metastasis sites, no visceral organ metastasis)
✓. Willing to sign the informed consent
✓. ECOG performance status Grade 0-2

Exclusion criteria

✕. Unable to tolerate the PET/CT scan, such as those with claustrophobia, unable to lie still, consciousness unclear, vital sign unstable.
✕. With renal impairment (glomerular filtration rate lower than 30 ml/min/1.73 m2), and allergy to medium contrast.
✕. Significant abnormal lab data (AST or ALT more than three times of normal value), and high risk to conduct examination after evaluations of PI.
✕. Patient had previous other malignancy history
✕. Patient experiences grade 3-4 neutropenia (neutrophil counts less than 1000/uL) or thrombocytopenia (platelet counts less than 50x103/uL) lasting \> 14 days

What they're measuring

Change of lesion detection number by PET imaging

Timeframe: 9-11 weeks or 21-23 weeks

Trial details

NCT IDNCT04951817

SponsorChang Gung Memorial Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-31

Contact for this trial

Jing-Ren Tseng, MD

0975-361-314 b9105019@gmail.com

View on ClinicalTrials.gov More Metastatic Prostate Cancer trials